Butyrolactone I reversibly inhibits meiotic maturation of bovine oocytes,Without influencing chromosome condensation activity.
In this study, butyrolactone I (BL I), a potent and specific inhibitor of cyclin-dependent kinases, was shown to block germinal vesicle (GV) breakdown (GVBD) in bovine oocytes in a concentration-dependent manner; GVBD was almost totally inhibited over the course of 24-48 h of culture when 100 microM BL I was included in tissue culture medium 199 containing either polyvinyl alcohol or BSA. Correlated with this inhibition was the failure of either p34(cdc2) kinase or mitogen-activated protein (MAP) kinase to become activated, and it was unlikely that BL I directly inhibited MAP kinase, since 100 microM BL I did not inhibit MAP kinase activity present in extracts obtained from metaphase II-arrested bovine eggs that possess high levels of MAP kinase activity. Nevertheless, the formation of highly condensed bivalents was observed in 78% of the BL I-treated GV-intact oocytes. This result suggests that chromosome condensation during first meiosis in bovine oocytes does not require the activity of either p34(cdc2) kinase or MAP kinase. Treatment of BL I-arrested oocytes with okadaic acid (OA) did not result in either the activation of p34(cdc2) kinase or MAP kinase, or inducement of GVBD. The BL I-induced block of GVBD for 24 h was reversible, and a subsequent 24-h culture resulted in 90% of oocytes reaching metaphase II with emission of the first polar body. Correlated with the progression to and arrest at metaphase II was the full activation of both p34(cdc2) and MAP kinases. The reversibility after 48 h of culture in BL I was partially decreased when compared to that achieved after an initial 24-h culture. Fertilization in vitro of these eggs resulted in a high incidence of both sperm penetration and pronucleus formation (88% and 70%, respectively).
Kubelka
M
M
Institute of Animal Physiology and Genetics, 277 21 Libechov, Czech Republic.
Motlík
J
J
Schultz
R M
RM
Pavlok
A
A
D015107:4-Butyrolactone / Q000031:analogs & derivatives* / Q000494:pharmacology; D000818:Animals; D015153:Blotting, Western; D016203:CDC2 Protein Kinase / Q000378:metabolism; D002417:Cattle; D002478:Cells, Cultured; D002843:Chromatin / Q000648:ultrastructure; D002875:Chromosomes / Q000187:drug effects*; D003470:Culture Media; D004591:Electrophoresis, Polyacrylamide Gel; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005260:Female; D005306:Fertilization / Q000502:physiology; D015571:Follicular Fluid / Q000166:cytology; D018858:Germinal Center / Q000187:drug effects; D008297:Male; D008540:Meiosis / Q000187:drug effects*; D020928:Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D004676:Myelin Basic Protein / Q000378:metabolism; D009865:Oocytes / Q000187:drug effects* / Q000201:enzymology / Q000254:growth & development*; D011494:Protein Kinases / Q000378:metabolism; D013094:Spermatozoa / Q000502:physiology; D016707:Tissue Fixation
D002843:Chromatin; D003470:Culture Media; D004791:Enzyme Inhibitors; D004676:Myelin Basic Protein; C082868:butyrolactone I; D011494:Protein Kinases; C102333:histone H1 kinase; D016203:CDC2 Protein Kinase; D020928:Mitogen-Activated Protein Kinases; D015107:4-Butyrolactone